0
Abstract: Poster Presentations |

TUBERCULOSIS WITH EXTENSIVE RESISTANCE TO DRUGS IN A TUBERCULOSIS REFERENCE CENTER IN SπO PAULO BRAZIL FREE TO VIEW

Marcia Telma G. Savioli, MD*; Jorge I. Neto, MD; Elisabete A. Almeida, BS; Nelson Morrone, MD; Fernando F. Melo, MD; Maria T. Ortega, MD; Denise S. Rodrigues, MD
Author and Funding Information

Instituto Clemente Ferreira, Sao Paulo, Brazil


Chest


Chest. 2009;136(4_MeetingAbstracts):73S-c-74S. doi:10.1378/chest.136.4_MeetingAbstracts.73S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  Mycobacterium tuberculosis resistant to at all second-line drugs (XDR-TB) has been emerged worldwide and become a threat to tuberculosis control. The aim of this work was to determine the occurrence of XDR-TB, as well as the epidemiological, clinical and bacteriological characteristic of these patients.

METHODS:  From 1994 to 2008, about 700 patients were considered MDR-TB. This report includes those isolates whose cultures were tested for susceptibility to second-line drugs, after what they could be considered as XDR-TB. It was evaluated: epidemiological, clinical and bacteriological patient characteristics, treatment outcomes, variation of susceptibility profiles of patient between different samples, and primary or secondary characteristic of resistance.

RESULTS:  To access the XDR-TB problem, second-line testing was analyzed on isolates from MDR-TB patients identified in routine drug-resistant of ours center. Among all patients, 17 (2.4%) had XDR-TB. Primary resistance was identified in three cases. Three patients were HIV-positive and two had diabetes mellitus. In all patients were collected at least two sputum with culture performed ai different moments. In the patient follow up, we identified 5 successfully treated, 11 failed and 6 died. Only one case was cured upon chirurgic intervention. There was no correlation between cures, failed, susceptibility test and treatment regime. Patients received individualized treatment that consisted of amicacin, ofloxacin and at least 3 other drugs. It was observed 68% of resistance for ofloxacin. Patients had a long-term follow-up of 1 to 10 years after MDR-TB diagnostic.

CONCLUSION:  There is an urgent need for more accurate monitoring systems for XDR-TB especially in countries with a high TB burden. It is preoccupant the increased cases of resistance to ofloxacin as it is included in the most MDR-TB therapy. Although, in most of case, XDR-TB has a poor prognostic, patients can be cured, or at least stabilized.

CLINICAL IMPLICATIONS:  The prevalence of XDR tuberculosis continues to rise, which requires a multifaceted approach to address this epidemic.

DISCLOSURE:  Marcia Telma Savioli, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543